Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Clinical research trials and Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia. Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia clinical trial. Test subjects typically obtain the finest healthcare available for their Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia



Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

For Condition: recurrent childhood acute myeloid leukemia,adult acute promyelocytic leukemia (M3),childhood acute promyelocytic leukemia (M3),recurrent adult acute myeloid leukemia
Status: Recruiting
Sponsor(s): Washington University Siteman Cancer Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide in treating patients with refractory or recurrentacute promyelocytic leukemia.
Details: OBJECTIVES: - Determine the maximum tolerated dose or minimum effective dose of arsenic trioxide in patients with refractory or recurrent acute promyelocytic leukemia. - Determine the efficacy of arsenic trioxide in this patient population. - Determine the acute and chronic toxicities of arsenic trioxide in this patient population. OUTLINE: This is a dose-escalation study. Patients receive arsenic trioxide IV over 2 hours daily for 28 days followed by a 14 day rest period. Patients may receive up to 3 courses of treatment. Dose escalation continues in cohorts of 3-6 patients until the maximum tolerated dose (MTD) or minimum effective dose (MED) is determined. The MTD is defined as the dose preceding that at which 2 or more patients experience dose limiting toxicity. The MED is defined as the dose at which 4 of 6 patients achieve a complete cytogenetic or molecular response. After the MTD or MED is determined, an additional 20 patients are enrolled at this dose level. Patients are followed monthly for 6 months and every three months for an additional 1.5 years. PROJECTED ACCRUAL: Approximately 32 patients will be accrued for this study within 3 years.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Pathologically confirmed acute promyelocytic leukemia (APML) (M3) - In first or subsequent relapse following standard induction and consolidation chemotherapy (with tretinoin) and/or allogeneic bone marrow/stem cell transplant OR - Failed to achieve initial complete remission with tretinoin and standard chemotherapy - No matched sibling donor available PATIENT CHARACTERISTICS: Age: - Any age Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - No renal failure - Creatinine clearance at least 25 mL/min Other: - Not pregnant - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics Chemotherapy: - See Disease Characteristics Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - No concurrent hemodialysis
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
JohnDiPersio,  Study Chair,  Washington University Siteman Cancer Center

Siteman Cancer Center *Recruiting*
St. Louis,  Missouri,  63110
United States
Recruiting John  DiPersio 314-454-8306


Additional Information:
Study ID Numbers:  CDR0000066617;  WU-98-0185,NCI-V98-1466
Study Start Date: 
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00008697

Other Adult Acute Promyelocytic Leukemia (m3) Studies:
1. Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

2. Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

3. Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

4. Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

5. Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Related Studies:

Other adult acute promyelocytic leukemia (M3) Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials

Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Modify your Search

  Other adult acute promyelocytic leukemia (M3) Clinical Trials
  Other Missouri Clinical Trials
  Other St. Louis Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103